Freeline Therapeutics Holdings plc

9.69+0.0500+0.52%Vol 24.65K1Y Perf -46.83%
Jun 14th, 2021 16:00 DELAYED
BID9.39 ASK9.80
Open9.81 Previous Close9.64
Pre-Market- After-Market-
 - -  - -%
Target Price
24.88 
Analyst Rating
— — 0.00
Potential %
156.76 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap347.33M 
Earnings Rating
Price Range Ratio 52W %
10.31 
Earnings Date
-

Today's Price Range

9.449.98

52W Range

8.3121.69

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.22%
1 Month
10.74%
3 Months
-27.79%
6 Months
-44.31%
1 Year
-46.83%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FRLN9.690.05000.52
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.78-0.98-25.64
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume24.65K
Shares Outstanding35.84M
Trades Count254
Dollar Volume133.75K
Avg. Volume19.59K
Avg. Weekly Volume24.19K
Avg. Monthly Volume63.84K
Avg. Quarterly Volume28.05K

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) stock closed at 9.69 per share at the end of the most recent trading day (a 0.52% change compared to the prior day closing price) with a volume of 24.65K shares and market capitalization of 347.33M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 236 people. Freeline Therapeutics Holdings plc CEO is Theresa Heggie.

The one-year performance of Freeline Therapeutics Holdings plc stock is -46.83%, while year-to-date (YTD) performance is -46.93%. FRLN stock has a five-year performance of %. Its 52-week range is between 8.31 and 21.69, which gives FRLN stock a 52-week price range ratio of 10.31%

Freeline Therapeutics Holdings plc currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 1.59, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.70%, a ROC of -52.34% and a ROE of -52.24%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Freeline Therapeutics Holdings plc, there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Freeline Therapeutics Holdings plc’s next earnings report date is -.

The consensus rating of Wall Street analysts for Freeline Therapeutics Holdings plc is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Freeline Therapeutics Holdings plc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Freeline Therapeutics Holdings plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Freeline Therapeutics Holdings plc has a Sell technical analysis rating based on Technical Indicators (ADX : 19.46, ATR14 : 0.92, CCI20 : 9.68, Chaikin Money Flow : -0.51, MACD : -0.19, Money Flow Index : 67.52, ROC : 5.90, RSI : 46.09, STOCH (14,3) : 22.82, STOCH RSI : 0.61, UO : 31.49, Williams %R : -77.18), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Freeline Therapeutics Holdings plc in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings PLC is a clinical stage, systemic AAV-based gene therapy company. The company is developing therapies for Haemophilia B, Fabry disease, Gaucher disease, and other diseases.

CEO: Theresa Heggie

Telephone: +44 1438906870

Address: Gunnels Wood Road, Stevenage SG1 2FX, Hertfordshire, GB

Number of employees: 236

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits